While there are well-studied injectable peptides used in medicine, namely insulin and GLP-1s, like Ozempic, these peptides that influencers push are neither approved by Health Canada nor have they been studied in large-scale human trials
(1) Parameters measure size, not enlargement (2) Parameters are arbitrary and unsupported (3) CKCSs have normal hearts above VHS 10.5 value (4) Heart-healthy CKCS has a LA/Ao ratio way below 1.6 (5) All Stage B2 sub-groups are lumped together (6) Recommended parameters ignored study's data (7) Study glosses over pimo causing sudden deaths (8) Report hides categories of pimo-caused adverse events (9) Early termination leads to risk of false positives (10) Study ignores contractility and systolic functions (11) Report excludes data of pimo shortening life spans in CHF (12) Report provides no breed-specific information (13) Authors try to defend manufacturer's control over them (14) Report contradicts earlier, misleading press releases But what is most disturbing is what is not in the EPIC Study report
If total exceeds $4,000, compounded semaglutide is cheaper
10.1016/j.febslet.2007.08.032 FEBS Lett
They fall for a Fool's Gold Standard of heart enlargement Dumbing-down diagnosing heart enlargement puts our cavaliers at high risk For the past 9 years (as of 2025), beginning with publication of the EPIC Study report in September 2016, numerous ACVIM board certified veterinary cardiologists have published articles in which they have defined left-sided cardiomegaly (heart enlargement) for any dog of any breed by two minimum echocardiograph measurements, one of the left atrium (LA/Ao = 1.6) and the other of the left ventricle (LVIDDN = 1.7)
